PTC Therapeutics
Healthcare & Life Sci
Company overview
PTC Therapeutics discovers, develops and sells medicines for children and adults with serious diseases. Founded in 1998, it is based in Warren Township, New Jersey. Its drug Emflaza treats Duchenne muscular dystrophy. Evrysdi, approved by the FDA in 2020, treats spinal muscular atrophy. Kebilidi, approved in 2024, is a gene therapy for AADC deficiency.
In 2025, PTC Therapeutics reported $1.73 billion in revenue and $683 million in net income. That is a lot of money for a company that treats rare, small patient populations. Historically, the median salary is ~$175,000. PTC Therapeutics is a top-tier H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cranbury, United States